Peggy Manders

Peggy Manders

UNVERIFIED PROFILE

Are you Peggy Manders?   Register this Author

Register author
Peggy Manders

Peggy Manders

Publications by authors named "Peggy Manders"

Are you Peggy Manders?   Register this Author

27Publications

464Reads

32Profile Views

Patients to learn from: on the need for systematic integration of research and care in academic health care.

J Clin Transl Res 2018 Dec 14;3(Suppl 3):401-406. Epub 2017 Sep 14.

Radboud Biobank, Radboud university medical center, Nijmegen, the Netherlands.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6412601PMC
December 2018

A Stepwise Procedure to Define a Data Collection Framework for a Clinical Biobank.

Biopreserv Biobank 2018 Apr 13;16(2):138-147. Epub 2018 Feb 13.

1 Radboud Biobank, Radboud University Medical Center , Nijmegen, the Netherlands .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/bio.2017.0084DOI Listing
April 2018

International biobanks: do or do not?

Future Sci OA 2015 Nov 22;1(4):FSO75. Epub 2015 Sep 22.

Radboud Biobank, Radboud University Medical Center, Nijmegen, The Netherlands; Radboud Biobank, Radboud University Medical Center, Nijmegen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4155/fso.15.75DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5138003PMC
November 2015

Accuracy of Hereditary Diffuse Gastric Cancer Testing Criteria and Outcomes in Patients With a Germline Mutation in CDH1.

Gastroenterology 2015 Oct 11;149(4):897-906.e19. Epub 2015 Jun 11.

Department of Pathology, Radboud university medical center, Nijmegen, The Netherlands; Department of Human Genetics, Radboud university medical center, Nijmegen, The Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.gastro.2015.06.003DOI Listing
October 2015

Validation study suggested no differential misclassification of self-reported mammography history in BRCA1/2 mutation carriers.

J Clin Epidemiol 2011 Dec 20;64(12):1434-43. Epub 2011 Jul 20.

Department of Epidemiology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jclinepi.2011.04.005DOI Listing
December 2011

Physical activity and the risk of breast cancer in BRCA1/2 mutation carriers.

Breast Cancer Res Treat 2010 Feb 13;120(1):235-44. Epub 2009 Aug 13.

Department of Epidemiology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-009-0476-0DOI Listing
February 2010

Reliability of self-reported diagnostic radiation history in BRCA1/2 mutation carriers.

Eur J Epidemiol 2010 Feb;25(2):103-13

Department of Epidemiology, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10654-009-9416-x
Publisher Site
http://dx.doi.org/10.1007/s10654-009-9416-xDOI Listing
February 2010

Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.

Am J Hum Genet 2008 Apr 20;82(4):937-48. Epub 2008 Mar 20.

Cancer Research UK, Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajhg.2008.02.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427217PMC
April 2008

High survivin predicts a poor response to endocrine therapy, but a good response to chemotherapy in advanced breast cancer.

Breast Cancer Res Treat 2006 Jul 16;98(2):223-30. Epub 2006 Mar 16.

Department of Chemical Endocrinology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-005-9153-0DOI Listing
July 2006

Survivin is an independent prognostic marker for risk stratification of breast cancer patients.

Clin Chem 2004 Nov 13;50(11):1986-93. Epub 2004 Sep 13.

Departments of Chemical Endocrinology, Clinical Chemistry, Medical Oncology, University Medical Center Nijmegen, Nijmegen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1373/clinchem.2004.039149DOI Listing
November 2004

Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success.

J Pathol 2004 Apr;202(4):395-402

Department of Chemical Endocrinology, University Medical Center Nijmegen, Nijmegen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/path.1528DOI Listing
April 2004

Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma.

Cancer 2003 Nov;98(10):2125-32

Department of Chemical Endocrinology, University Medical Center Nijmegen, Nijmegen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.11764DOI Listing
November 2003

Molecular beacon reverse transcription-PCR of human chorionic gonadotropin-beta-3, -5, and -8 mRNAs has prognostic value in breast cancer.

Clin Chem 2003 Jul;49(7):1074-80

Department of Chemical Endocrinology, University Medical Center Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands.

View Article

Download full-text PDF

Source
July 2003

Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer.

Oncogene 2003 Jul;22(31):4898-904

Department of Chemical Endocrinology, University Medical Center Nijmegen, Nijmegen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.onc.1206818DOI Listing
July 2003

E1AF expression levels are not associated with prognosis in human breast cancer.

Breast Cancer Res Treat 2003 May;79(1):129-31

Department of Chemical Endocrinology, University Medical Center Nijmegen, Nijmegen, The Netherlands.

View Article

Download full-text PDF

Source
May 2003

Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer.

Oncogene 2002 Dec;21(55):8506-9

Department of Chemical Endocrinology, University Medical Center Nijmegen, Nijmegen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.onc.1206040DOI Listing
December 2002